Harrow
Dennis E. Saadeh is the Chief of Formulation Strategy for Harrow. A pharmacist by education and training, he has over 20 years of relevant drug development experience in a variety of settings. His current responsibilities include pre-formulation and formulation development for a multitude of drug product candidates. Additionally, he contributes and collaborates with the Harrow intellectual property team, analytical development group, active pharmaceutical suppliers and contract manufacturers to execute company initiatives. Prior to Harrow, from 1996 to 2015, Dr. Saadeh founded Park Compounding, a specialty pharmacy dedicated to the individual needs of integrative practitioners, including the development of many unique formulations that support the treatment of chronic diseases. He has also participated in numerous clinical research studies for clinical research organizations and pharmaceutical companies related to the treatment of a variety of conditions. In 2012, Dr. Saadeh founded Integrative Therapies Institute (ITI), an educational organization bringing together highly specialized lecturers covering medical conditions and treatment protocols at annual conferences. Dr. Saadeh has his Doctor of Pharmacy degree from the University of Southern California and obtained his Fellowship in the American College of Apothecaries in 2005.
This person is not in any offices
Harrow
2 followers
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.